Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA).
S Møller-BisgaardB J EjbjergI EshedKim Hørslev-PetersenM L HetlandA G JurikH ThomsenT TorfingK Stengaard-PedersenP JunkerN S KroghT LottenburgerT EllingsenL S AndersenH SkjødtA J SvendsenU TarpI T HansenJ PødenphantJ K PedersenH LindegaardL G HansonA VestergaardD GlinatsiM ØstergaardPublished in: Scandinavian journal of rheumatology (2016)
In this eRA treat-to-target trial, MTX and intra-articular glucocorticoids markedly reduced, but did not eliminate, MRI osteitis, synovitis, and tenosynovitis. Accordingly, minimal but statistically significant increases in bone erosion and JSN were observed. No additional effect of CyA was demonstrated.
Keyphrases
- double blind
- phase iii
- placebo controlled
- clinical trial
- phase ii
- study protocol
- rheumatoid arthritis
- contrast enhanced
- bone mineral density
- magnetic resonance imaging
- diffusion weighted imaging
- open label
- bone loss
- soft tissue
- bone regeneration
- disease activity
- high dose
- body composition
- randomized controlled trial
- ankylosing spondylitis
- systemic sclerosis